CYCN: Cyclerion Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 8.08
Enterprise Value ($M) 2.38
Book Value ($M) 9.92
Book Value / Share 3.66
Price / Book 0.81
NCAV ($M) 4.57
NCAV / Share 1.69
Price / NCAV 1.77

Profitability (mra)
Return on Invested Capital (ROIC) 0.02
Return on Assets (ROA) 0.01
Return on Equity (ROE) 0.04

Liquidity (mrq)
Quick Ratio 4.17
Current Ratio 4.17

Balance Sheet (mrq) ($M)
Current Assets 6.01
Assets 11.36
Liabilities 1.44
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -9.65
Net Income -5.26
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -21.25
Cash from Investing 10.40
Cash from Financing 5.02

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Tyndall Capital Partners L P 6.70 35.18
02-09 13G/A Artal International S.C.A. 5.70 -95.00
02-09 13G/A Fmr Llc 6.66
01-22 13G/A Slate Path Capital LP 14.60
12-05 13D/A Hecht Peter M 62.19

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-03-05 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-07-28 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-16 8 1,054 0.76
2024-05-14 229 657 34.86
2024-05-13 6 38 15.79

(click for more detail)

Similar Companies
CUE – Cue Biopharma, Inc. CVKD – Cadrenal Therapeutics, Inc.
CYCC – Cyclacel Pharmaceuticals, Inc. CYRX – Cryoport, Inc.
CYTH – Cyclo Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io




This entry was posted in . Bookmark the permalink.